Buy CELZ by May 14, 2027.

Creative Medical Technology Holdings is a clinical-stage biotech advancing stem cell-based therapies, currently trading around $2.17. Here's an overview of where things stand: The Basics CELZ is developing regenerative treatments across immunology, endocrinology, urogynecology, and orthopedics. Its lead program, CELZ-201 (Olastrocel), is being evaluated for chronic lower back pain and Type 1 diabetes. Key Catalysts * FDA Fast Track designation secured for CELZ-201-DDT (degenerative disc disease) * Interim ADAPT trial data showed statistically significant improvements in pain and function - …